'Some Hope Is Better Than Having No Hope'

This past weekend, the chairman of the Federal Communications Commission threatened to revoke broadcasters’ licenses over their coverage of the war in Iran. Last month, Stephen Colbert said he had to drop an interview with a Senate candidate because of F.C.C. guidance that target ...  Show more

At the heart of the Iranian regime’s defiant stance toward the United States and Israel in the war is Mojtaba Khamenei, the new supreme leader and a son of Ayatollah Ali Khamenei, the regime’s longtime ruler. Farnaz Fassihi, who covers Iran for The New York Times, discusses the e ...  Show more

For many years, pharmaceutical companies have tried and failed to find a treatment to slow symptoms of ALS–the debilitating, fatal illness also known as Lou Gehrig’s Disease. A potentially promising new drug from Biogen may offer some relief to those afflicted with an uncommon an ...  Show more

The FDA has approved a new drug for Alzheimer's. But a lot of experts are skeptical about whether the drug works. Rhitu Chatterjee talks with science correspondent Jon Hamilton about the controversial drug aducanumab and why the U.S. Food and Drug Administration approved it. For ...  Show more

Aduhelm, known generically as aducanumab, is the first drug to actually affect the underlying disease process associated with Alzheimer's. Yet sales have been limited, and the drug is reaching very few patients — at least so far. It's expensive, risky and likely doing little to i ...  Show more

An overwhelming demand for ADHD diagnoses has left the NHS struggling to keep up. What’s behind the rise?

Content warning: This episode contains mentions of suicidal thoughts and eating disorders.

This podcast was brought to you thanks to the s ...